- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.11. | Journey Medical, with FDA nod, won't stop believing it can establish new rosacea standard of care | ||
| 04.11. | In defense of radioligand therapies, Novartis fired off patent lawsuits against Lilly and other rivals | ||
| 04.11. | AstraZeneca backs American Lung Association campaign to improve lives of COPD patients | ||
| 04.11. | Incyte wins injunction to block launch of Sun Pharma's JAK inhibitor Leqselvi | ||
| 04.11. | Dr. Reddy's pulls more than 300K bottles of thyroid drug, citing presence of a carcinogen | ||
| 01.11. | Argenx' Vyvgart launch in CIDP picks up as the company barrels toward 10 indications by 2030 | ||
| 01.11. | In FDA adcomm, Lexicon gets another thumbs down for type 1 diabetes hopeful Zynquista | ||
| 01.11. | Novo Nordisk's semaglutide delivers in phase 3 MASH study, teeing up filings | ||
| 01.11. | Novartis sings a new tune as official partner of Eurovision Song Contest 2025 | ||
| 01.11. | 'It was a good lesson': FDA reconsiders CAR-T boxed warning on secondary cancers, Peter Marks says | ||
| 01.11. | After prior settlements, Apotex and Heritage hand over a combined $49M to resolve longstanding price-fixing claims | ||
| 01.11. | Fierce Pharma Asia-AstraZeneca exec under investigation in China; GSK's lupus deal; Takeda's orexin hiccup | ||
| 31.10. | It's a monster MASH for Madrigal as Rezdiffra has caught on in a flash | ||
| 31.10. | FDA removes Novo's Wegovy from shortage list, marking end of semaglutide supply rout in US | ||
| 31.10. | Gardasil's China troubles haunt Merck in Q3, with execs warning of more obstacles ahead | ||
| 31.10. | Regeneron's Eylea HD makes progress but doesn't dent the momentum of Roche's Vabysmo | ||
| 31.10. | Boehringer, Amgen, Novartis sweep corporate reputation rankings among cardiovascular patient groups | ||
| 31.10. | Teva slapped with €463M fine over accusations it stymied Copaxone competition in Europe | ||
| 31.10. | As new drugs deliver, Bristol Myers CEO looks to 'further improve productivity and efficiency' | ||
| 31.10. | Novo Nordisk hit with FDA write-up over production issues at critical semaglutide plant | ||
| 31.10. | Amgen reaps Horizon buyout rewards in Q3 as it gears up for key biosim launches | ||
| 30.10. | Baxter exits China IV fluids market amid tough local competition, US shortage | ||
| 30.10. | UK's Labour Party unveils £520M innovative manufacturing fund as part of life-sci-heavy budget | ||
| 30.10. | Evolving & Expanding Integrated Platform Partnerships to Drive Access, Affordability & Outcomes | ||
| 30.10. | AbbVie's Skyrizi snatches sales crown from Humira as company lifts full-year profit guidance |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
